ELVN Projected Dividend Yield
Enliven Therapeutics Inc ( NASDAQ : ELVN )Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, and other serious diseases. Co.'s pipeline is built on the differentiated therapeutic potential of its primary product candidate, tovinontrine (IMR-687), which is an oral, small molecule inhibitor of phosphodiesterase-9. Tovinontrine is in Phase 2b clinical development for the treatment of sickle cell disease and ß-thalassemia. Co. is also developing IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2?related factor 2. 20 YEAR PERFORMANCE RESULTS |
ELVN Dividend History Detail ELVN Dividend News ELVN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |